Lumbar Assistive Exoskeletons in Caregiving (ExoCare)
"Effectiveness of Lumbar Assistive Exoskeleton in Nursing Home Caregivers: Randomized Control Trial"
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ana Rodriguez Larrad, PhD
- Phone Number: 0034946017925
- Email: ana.rodriguez@ehu.eus
Study Contact Backup
- Name: Maialen Aiestaran, MsC
- Phone Number: 0034946017925
- Email: maialen.aiestaran@ehu.eus
Study Locations
-
-
Bizkaia
-
Leioa, Bizkaia, Spain, 48940
- Recruiting
- IFAS/GUFE Centro Asistencial Leioa
-
-
Vizcaya
-
Elorrio, Vizcaya, Spain, 48230
- Recruiting
- IFAS/GUFE Centro Asistencial Elorrio
-
Contact:
- Phone Number: +34 946583231
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- nursing home caregivers
Exclusion Criteria:
- pregnancy
- presence of condition that prevents from the use of a lumbar exoskeleton
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control Group
Participants randomly assigned to control group will not wear an exoskeleton during working hours.
|
|
|
Experimental: Exoskeleton Group
Participants randomly assigned to exoskeleton group will be given instructions and explanations on how to use/adjust/loosen the exoskeleton, and after a period of familiarisation, they will be wearing an exoskeleton during their working hours for a period of one year.
|
Lumbar assistive exoskeleton evaluation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Pain Intensity at 3 months
Time Frame: At Baseline and at 3 months
|
Average pain intensity during the last 7 days in a Numerical Rating Scale for pain ranging from 0 (complete absence of pain) to 10 (worst imaginable pain).
This information will be collected for pain in the low back, neck, shoulders and wrists/hands
|
At Baseline and at 3 months
|
|
Change from baseline Pain Intensity at 6 months
Time Frame: At Baseline and at 6 months
|
Average pain intensity during the last 7 days in a Numerical Rating Scale for pain ranging from 0 (complete absence of pain) to 10 (worst imaginable pain).
This information will be collected for pain in the low back, neck, shoulders and wrists/hands
|
At Baseline and at 6 months
|
|
Change from baseline Pain Intensity at 9 months
Time Frame: At Baseline and at 9 months
|
Average pain intensity during the last 7 days in a Numerical Rating Scale for pain ranging from 0 (complete absence of pain) to 10 (worst imaginable pain).
This information will be collected for pain in the low back, neck, shoulders and wrists/hands
|
At Baseline and at 9 months
|
|
Change from baseline Pain Intensity at 12 months
Time Frame: At Baseline and at 12 months
|
Average pain intensity during the last 7 days in a Numerical Rating Scale for pain ranging from 0 (complete absence of pain) to 10 (worst imaginable pain).
This information will be collected for pain in the low back, neck, shoulders and wrists/hands
|
At Baseline and at 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Usability measured by System Usability Scale
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
It is a simple scale of ten items that provides a subjective global vision of the usability of the evaluated exoskeleton on a scale of 1 to 5 (1 being strongly disagree and 5 strongly agree).
Higher values mean the users found the device more usable.
|
Baseline, month 3, month 6, month 9, post intervention
|
|
User Satisfaction measured by Quebec User Evaluation of Satisfaction with Assistive Technology
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
Scale to evaluate the satisfaction of the person during the use of the exoskeleton.
It is made up of two subscales: the first considers eight aspects related to the support product (in this case, the exoskeleton); the second subscale evaluates four items regarding maintenance services during the use of the device.
The scale goes from 1 (not satisfied at all) to 5 (very satisfied).
Higher values mean that users are more satisfied.
|
Baseline, month 3, month 6, month 9, post intervention
|
|
Self-reported work ability by Work Ability Index
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
It yields a continuous score ranging from 7 to 49 points, where higher scores indicate better work ability.
|
Baseline, month 3, month 6, month 9, post intervention
|
|
Borg's CR-10 scale for perceived physical exertion at work
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
It measures perceived physical exertion while doing physical work in a scale ranging from 0 (nothing at all) to 10 (extremely strong).
|
Baseline, month 3, month 6, month 9, post intervention
|
|
Muscular resistance of the trunk muscles measured by the "Shirado-Ito" test
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
It measures trunk muscle endurance based on the maximum time the participant is able to maintain a defined body position.
|
Baseline, month 3, month 6, month 9, post intervention
|
|
Discomfort measured by Body Part Discomfort Scale
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
Survey of subjective symptoms that evaluates both the direct experience of discomfort of the person surveyed in different parts of the body, as well as the intensity of said discomfort on a scale of 0 to 10 (0 being no discomfort and 10 extremely high discomfort).
|
Baseline, month 3, month 6, month 9, post intervention
|
|
Absenteeism
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
Days of absence from work will be collected from the official registry of the company and by the following question: "In total, how many days of work have you missed due to health reasons (injury, illness, medical consultation / treatment ...) during the last 12 weeks?".
Possible answers will be: "0 days", "1-7 days", "8-30 days", "more than 30 days".
In addition, number of days of absenteeism during the last 7 days (0-7) will be recorded.
|
Baseline, month 3, month 6, month 9, post intervention
|
|
Musculoskeletal disorders prevalence
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
Prevalence of musculoskeletal injuries such as tendinopathies, unspecific low back pain
|
Baseline, month 3, month 6, month 9, post intervention
|
|
Prevalence of Side Effects
Time Frame: Baseline, month 3, month 6, month 9, post intervention
|
Side effects secondary to the use of the exoskeleton such as: chafe, irritation, pressures.
|
Baseline, month 3, month 6, month 9, post intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Ana Rodriguez Larrad, PhD, Professor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ExoCare
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.